Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$322,000.00
Jul 1, 2025
For-profit organization
AI-Driven Advanced Imaging Device for Biomarker Identification in Histology Slides
1034070
illumiSonics is developing the Photon Absorption Remote Sensing (MLI®) Advanced Imaging Device (AID), a high-resolution, label-free imaging system that enhances digital pathology through multiplexed virtual staining of unstained FFPE tissue. By capturing multiple optical contrasts in a single scan, the device enables AI-driven image reconstruction of standard histological stains, such as H&E and Masson’s Trichrome. The project will finalize and validate the system, deploy it to a research partner, and generate revenue through scan-per-use and licensing models in support of translational research, biomarker discovery, and advanced cancer diagnostic tests.
$100,000.00
Jul 1, 2020
For-profit organization
Commercial Development of Non-Contact Photoacoustic Remote Sensing Optical Microscopy for Rapid Tissue Analysis
953120
There is a desperate need for a fast, non-contact, non-invasive, safe and accurate technique that can measure oxygen saturation, oxygen metabolic activity, and multilayered histology-like information. Quickly acquiring in-situ microscope images of disease morphology and oxygen metabolic activity can play a vital role in understanding, and better treating, several diseases including cancers and vision loss. We aim to develop a rapid label-free clinical imaging tool that can visualize tissue structure by leveraging our PARS™ technology. This is carried out in collaboration with clinicians and our optical technical development team.
$146,000.00
Dec 1, 2018
For-profit organization
Photoacoustic Remote Sensing (PARS) Microscopy for Pre-clinical and Clinical Applications
917711
There is a desperate need for a fast, non-contact, non-invasive, safe and accurate technique that can measure oxygen saturation, oxygen metabolic activity, and multilayered histology-like information. Quickly acquiring in-situ microscope images of disease morphology and oxygen metabolic activity can play a vital role in understanding, and better treating, several diseases including cancers and vision loss. To achieve this, Histological and Functional Photoacoustic Remote Sensing (HF-PARS) microscopy is being developed to provide a quick, easy-to-use, reliable, and high resolution non-contact photo-acoustic based microscopy. This can easily be incorporated into current patient care and improve diagnosis and treatment these diseases.
$10,000.00
Jul 2, 2018
For-profit organization
Photoacoustic Remote Sensing - Youth-Green
909652
This project's goal is to establish clinical applications for PARS and facilitate its translation to clinical use. We will work with clinician partners that will help field test initial prototypes on patients in ethics approved clinical trials conducted at the University of Alberta and the Cross Cancer Institute, Edmonton, Canada.